Adult Pneumococcal Hospitalizations Rise Despite Vaccines

A study presented at IDWeek 2026 found adult invasive pneumococcal disease hospitalizations increased even as higher-valency vaccines became available.

Updated on Nov. 3, 2026 in Diseases — General

Isometric editorial illustration of a row of amber glass vials on a clinical tray beside a syringe, rendered in muted cream, slate, and teal. — Adult hospitalizations from invasive pneumococcal disease rose between 2006 and 2024 despite higher-valency vaccines, while pediatric rates held steady, researchers reported at IDWeek 2026. AI Illustration. Upload story photo >

Live Poll

Have you kept up with your recommended pneumococcal vaccine shots as an adult?

Researchers presenting at IDWeek 2026 in Washington, DC, reported that adult invasive pneumococcal disease hospitalizations rose significantly between 2006 and 2024 despite the availability of higher-valency vaccines. Pediatric hospitalization rates remained unchanged over the same period.

Why it matters

The findings suggest that expanded pneumococcal vaccine coverage has not translated into fewer adult hospitalizations in commercially insured populations. For U.S. adults, the results raise questions about how current vaccine strategies are performing outside the pediatric population.

Using commercial insurance claims, the analysis compared 2022-2024 hospitalizations with a 2006-2019 baseline, and 54.4% of cases occurred in patients aged 50-64 across 204,479 total hospitalizations. Adult IPD hospitalization rate ratios ranged from 1.16 to 1.23 versus baseline, while pediatric ratios ranged from 0.96 to 1.05.

The details

Investigators stratified patients into 0-2, 3-17, 18-49, and 50-64 year age groups and used generalized linear quasi-Poisson regression to analyze trends. Data from 2020 and 2021 were excluded because of the COVID-19 pandemic, and the higher-valency period covered years in which PCV15, PCV20, and PCV21 were available.

2006 to 2019: Baseline period when PCV7 and PCV13 were available.
2020 to 2021: Data excluded due to the COVID-19 pandemic.
2022 to 2024: Higher-valency vaccine period with PCV15, PCV20, and PCV21 available.
October 21 to 24, 2026: IDWeek 2026 held in Washington, DC, where results were presented.

Big Picture

The findings were presented at IDWeek 2026, the annual meeting of the Infectious Diseases Society of America, and add adult-focused data to the ongoing evaluation of higher-valency pneumococcal vaccines introduced after PCV13. The pediatric stability alongside adult increases contrasts with the population-level gains typically associated with childhood vaccination programs.

Adults who have been told they are at risk of pneumococcal disease should review current vaccine recommendations with their clinicians, since the study suggests newer vaccines have not yet lowered adult hospitalization rates. Commercially insured adults aged 50 to 64, who accounted for more than half of cases in the analysis, are the group most directly reflected in these findings.

The takeaway

Higher-valency vaccines alone have not been sufficient to reverse rising adult pneumococcal hospitalizations, so vaccination decisions should be reviewed with a healthcare provider rather than assumed to offer full protection. Monitoring of serotype coverage and adult vaccine uptake remains important as new formulations are rolled out.